Clinical Trial Search

Primary: Change From Baseline In Young-Mania Rating Scale (YMRS) Score At Week 3 — -12.3; -10.7 units on a scale — p==0.1011

Primary: Human Serum Bactericidal Activity (hSBA) Adjusted Geometric Mean Titers (GMTs) Against All of N. Meningitidis Serogroup B Test Strains (Pooled), One Month After Last…

Primary: Best Overall Response Rate (BORR) — 2; 17; 1 Participants

Primary: Feasibility of Providing Intervention — 25; 22 Participants

Primary: Safety: Number of Participants With at Least One Adverse Event — 10 Participants — p=<0.05

Primary: Number of Subjects With Treatment-emergent Adverse Events (TEAEs) — 10; 10; 10; 10 Participants

Primary: Percentage of Participants Achieving Age-Specific Kidney Disease Outcomes Quality Initiative (KDOQI) Targets for Serum Phosphate Level Following 8 Weeks of Lanthanum…

Primary: The Primary Safety Endpoint is the Number and Percentage of Participants Per Dose Group and Randomized Allocation, With at Least One of the Following Adverse Events…

Primary: Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity — 17.2; 21.9; 29.7; 45.3 Percentage of Participants

Primary: Maximal Oxygen Consumption (Peak VO2) — 16; 17; 15.3; 14.2 ml/kg/min

Primary: Absolute Change From Baseline in HDL-C Level\n — 17.18; 31.42; 36.45; 2.31 mg/dL

Primary: Percentage of Participants Who Achieved 0.25 Logarithm to the Base 10 (Log10) Hepatitis B Surface Antigen (HBsAg) Reduction From the Baseline at Week 48 — 4; 96…

Primary: Number of Blood Tests for Bilirubin Measurement (Before the Potential Start of Phototherapy). — 0; 1 blood tests for bilirubin

Primary: Number of Participants With Adverse Drug Reactions — 15; 0 Particpants

Primary: Change From Baseline in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) — -3.2; -3.7 Score on a Scale — p=0.4421